You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Displaying Drugs List

169 Items
Other Name(s): Zytiga® (Janssen)
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
Aug 2018
Other Name(s): Giotrif® (Boehringer Ingelheim)
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Aug 2017
Other Name(s): Zaltrap® (Sanofi-aventis)
Apr 2017
Other Name(s): Proleukin® (interleukin-2) (Novartis)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
May 2018
Other Name(s): Alecensaro™ ()
Aug 2018
Other Name(s): MabCampath® (Sanofi Genzyme)
Apr 2016
Other Name(s): AMSA P D® (Erfa)
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Jul 2017
Other Name(s): Arimidex® (multiple brands available)
Funding:
ODB Limited Use
  • anastrozole - For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women
  • anastrozole - An alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer
Apr 2016
Other Name(s): Erleada® ()
Nov 2018
Other Name(s): Trisenox® (Lundbeck)
Funding:
New Drug Funding Program
  • Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Apr 2016
Aug 2016